Clinical Perspectives and Novel Preclinical Models of Malignant Pleural Mesothelioma: A Critical Review

Aliakbar Ebrahimi ¹, Güntülü Ak ², Ceren Özel ^1,3

⁰Cellular Therapy and Stem Cell Production Application and Research Center (ESTEM), Eskişehir Osmangazi University, Eskişehir 26040, Turkey.

Acs Pharmacology & Translational Science +

|

November 14, 2024

View abstract on PubMed

Summary

Early diagnosis of pleural mesothelioma (PM) is crucial. This review explores advanced diagnostic tools, including microfluidic chips and 3D models, to improve outcomes for this rare asbestos-related cancer.

Area Of Science

Oncology
Biotechnology
Medical Diagnostics

Background

Pleural mesothelioma (PM) is a rare, aggressive cancer linked to asbestos exposure with poor prognosis.
Limited treatment options and delayed diagnosis contribute to its global health burden.
Current diagnostic methods for PM are insufficient for early detection.

Purpose Of The Study

To provide a comprehensive overview of pleural mesothelioma.
To evaluate advanced diagnostic and preclinical research technologies for PM.
To highlight the potential of microfluidic and 3D models in PM research and diagnosis.

Main Methods

Review of epidemiological, etiological, and clinical aspects of PM.
Investigation of disease-specific biomarkers in serum/plasma for early diagnosis.
Comprehensive analysis of advanced preclinical models: 3D cultures (spheroids, organoids, bioprinting, ex vivo slices) and microfluidic chip-based systems.

Main Results

Identification of potential serum/plasma biomarkers for early PM detection is discussed.
Advanced 3D models offer more physiologically relevant preclinical research platforms.
Microfluidic 'on-chip' models show promise for PM detection and therapeutic screening.

Conclusions

Early diagnosis is critical for improving pleural mesothelioma patient outcomes.
Advanced technologies like 3D models and microfluidic chips represent promising avenues for PM research and diagnostics.
Further development and validation are needed to translate these technologies into clinical practice.